Prostate cancer in East Asia: Evolving trend over the last decade

Asian Journal of Andrology

Volumn 17, Issue 1, 2015, Pages 48-57

  Zhu, Yao ^a,b   Wang, Hong Kai ^a,b   Qu, Yuan Yuan ^a,b   Ye, Ding Wei ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Asians; diagnosis; epidemiology; genetics; prostate cancer; treatment outcome

Indexed keywords

ANTINEOPLASTIC AGENT;

ANDROGEN DEPRIVATION THERAPY; CANCER CHEMOTHERAPY; CARCINOGENESIS; EAST ASIAN; ENVIRONMENTAL FACTOR; EXTERNAL BEAM RADIOTHERAPY; HEREDITY; HUMAN; MALE; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREND STUDY; DIET; DISEASE MANAGEMENT; FAR EAST; GENETICS; LIFESTYLE; PREVALENCE; PROSTATIC NEOPLASMS;

DIET; DISEASE MANAGEMENT; FAR EAST; HUMANS; LIFE STYLE; MALE; PREVALENCE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84920415028     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.132780     Document Type: Review

References (162)

1. United States Census Bureau, International Data Base 2008. 2008. web link: http://www.census.gov/population/international/data/idb/informationGateway.php.
2. Human Development Report, United Nations Development Programme, 2013; 2013.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. web link: http://globocan.iarc.fr/.
5. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, et al. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat 2013; 45: 1-14.
6. Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, et al. Cancer incidence and incidence rates in Japan in 2007: a study of 21 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2013; 43: 328-36.
7. Ghiringhelli F, Vincent J, Guiu B, Chauffert B, Ladoire S. Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies. Invest New Drugs 2012; 30: 758-64.
8. Miyato H, Kitayama J, Hidemura A, Ishigami H, Kaisaki S, et al. Vagus nerve preservation selectively restores visceral fat volume in patients with early gastric cancer who underwent gastrectomy. J Surg Res 2012; 173: 60-7.
9. Institute SC. Shanghai Cancer Incidence Data. web link: http://www.tumorsci.org/html/list-646.html.
10. Zhao P. Chinese Cancer Registry Annual Report. Military Medical Scientific publishers; 2009-2012.
11. Shao CX, Xiang YB, Liu ZW, Gao J, Sun L, et al. The analysis of the relative survival for urological cancer in urban Shanghai. Chin J Clin Oncol 2005; 32: 321-7.
12. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 2003; 289: 1414-20.
13. Chung MS, Lee SH, Lee DH, Kim SJ, Kim CS, et al. Practice patterns of Korean urologists for screening and managing prostate cancer according to PSA level. Yonsei Med J 2012; 53: 1136-41.
14. Kang HW, Kim D, Kim HJ, Kim CH, Kim YS, et al. Visceral obesity and insulin resistance as risk factors for colorectal adenoma: a cross-sectional, case-control study. Am J Gastroenterol 2010; 105: 178-87.
15. van Roermund JG, Bol GH, Witjes JA, Ruud Bosch JL, Kiemeney LA, et al. Periprostatic fat measured on computed tomography as a marker for prostate cancer aggressiveness. World J Urol 2010; 28: 699-704.
16. Matsuda T, Ajiki W, Marugame T, Ioka A, Tsukuma H, et al. Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study. Jpn J Clin Oncol 2011; 41: 40-51.
17. Ma CG, Ye DW, Li CL, Zhou FJ, Yao XD, et al. [Epidemiology of prostate cancer from three centers and analysis of the first-line hormonal therapy for the advanced disease]. Zhonghua Wai Ke Za Zhi 2008; 46: 921-5.
18. Gomez SL, Noone AM, Lichtensztajn DY, Scoppa S, Gibson JT, et al. Cancer incidence trends among Asian American populations in the United States, 1990-2008. J Natl Cancer Inst 2013; 105: 1096-110.
19. Hori S, Butler E, McLoughlin J. Prostate cancer and diet: food for thought? BJU Int 2011; 107: 1348-59.
20. Kolonel LN. Fat, meat, and prostate cancer. Epidemiol Rev 2001; 23: 72-81.
21. Lee MM, Wang RT, Hsing AW, Gu FL, Wang T, et al. Case-control study of diet and prostate cancer in China. Cancer Causes Control 1998; 9: 545-52.
22. Mishina T, Watanabe H, Araki H, Nakao M. Epidemiological study of prostatic cancer by matched-pair analysis. Prostate 1985; 6: 423-36.
23. Zheng J, Yang B, Huang T, Yu Y, Yang J, et al. Green tea and black tea consumption and prostate cancer risk: an exploratory meta-analysis of observational studies. Nutr Cancer 2011; 63: 663-72.
24. Kurahashi N, Sasazuki S, Iwasaki M, Inoue M, Tsugane S, et al. Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol 2008; 167: 71-7.
25. Yan L, Spitznagel EL. Meta-analysis of soy food and risk of prostate cancer in men. Int J Cancer 2005; 117: 667-9.
26. Park JW, Choi YJ, Suh SI, Kwon TK. Involvement of ERK and protein tyrosine phosphatase signaling pathways in EGCG-induced cyclooxygenase-2 expression in Raw 264.7 cells. Biochem Biophys Res Commun 2001; 286: 721-5.
27. Mäkelä S, Poutanen M, Kostian ML, Lehtimäki N, Strauss L, et al. Inhibition of 17beta-hydroxysteroid oxidoreductase by flavonoids in breast and prostate cancer cells. Proc Soc Exp Biol Med 1998; 217: 310-6.
28. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 1995; 87: 652-61.
29. Kruk J, Aboul-Enein HY. Physical activity in the prevention of cancer. Asian Pac J Cancer Prev 2006; 7: 11-21.
30. Shahar S, Shafurah S, Hasan Shaari NS, Rajikan R, Rajab NF, et al. Roles of diet, lifetime physical activity and oxidative DNA damage in the occurrence of prostate cancer among men in Klang Valley, Malaysia. Asian Pac J Cancer Prev 2011; 12: 605-11.
31. Park S, Bae J, Nam BH, Yoo KY. Aetiology of cancer in Asia. Asian Pac J Cancer Prev 2008; 9: 371-80.
32. World Health Organization. Noncommunicable Diseases Country Profiles 2011. Geneva: World Health Organization; 2011. p. 50.
33. Takata R, Akamatsu S, Kubo M, Takahashi A, Hosono N, et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet 2010; 42: 751-4.
34. Akamatsu S, Takata R, Haiman CA, Takahashi A, Inoue T, et al. Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nat Genet 2012; 44: 426-9, S1.
35. Xu J, Mo Z, Ye D, Wang M, Liu F, et al. Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat Genet 2012; 44: 1231-5.
36. Zheng J, Liu F, Lin X, Wang X, Ding Q, et al. Predictive performance of prostate cancer risk in Chinese men using 33 reported prostate cancer risk-associated SNPs. Prostate 2012; 72: 577-83.
37. Liu F, Hsing AW, Wang X, Shao Q, Qi J, et al. Systematic confirmation study of reported prostate cancer risk-associated single nucleotide polymorphisms in Chinese men. Cancer Sci 2011; 102: 1916-20.
38. Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009; 41: 1116-21.
39. Gudmundsson J, Sulem P, Rafnar T, Bergthorsson JT, Manolescu A, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008; 40: 281-3.
40. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008; 40: 316-21.
41. Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 2011; 43: 785-91.
42. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40: 310-5.
43. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007; 39: 631-7.
44. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39: 645-9.
45. Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007; 39: 638-44.
46. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007; 39: 977-83.
47. Lindström S, Schumacher FR, Campa D, Albanes D, Andriole G, et al. Replication of five prostate cancer loci identified in an Asian population-results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev 2012; 21: 212-6.
48. Yamada H, Penney KL, Takahashi H, Katoh T, Yamano Y, et al. Replication of prostate cancer risk loci in a Japanese case-control association study. J Natl Cancer Inst 2009; 101: 1330-6.
49. Zheng SL, Hsing AW, Sun J, Chu LW, Yu K, et al. Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men. Prostate 2010; 70: 425-32.
50. Troutman SM, Sissung TM, Cropp CD, Venzon DJ, Spencer SD, et al. Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis. Oncologist 2012; 17: 312-20.
51. Wiehagen KR, Corbo-Rodgers E, Li S, Staub ES, Hunter CA, et al. Foxp4 is dispensable for T cell development, but required for robust recall responses. PLoS One 2012; 7: e42273.
52. Ordóñez D, Sánchez AJ, Martínez-Rodríguez JE, Cisneros E, Ramil E, et al. Multiple sclerosis associates with LILRA3 deletion in Spanish patients. Genes Immun 2009; 10: 579-85.
53. Wisniewski A, Wagner M, Nowak I, Bilinska M, Pokryszko-Dragan A, et al. 6.7-kbp deletion in LILRA3 (ILT6) gene is associated with later onset of the multiple sclerosis in a Polish population. Hum Immunol 2013; 74: 353-7.
54. Wang L, McDonnell SK, Slusser JP, Hebbring SJ, Cunningham JM, et al. Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res 2007; 67: 2944-50.
55. Batra J, Lose F, Chambers S, Gardiner RA, Aitken J, et al. A replication study examining novel common single nucleotide polymorphisms identified through a prostate cancer genome-wide association study in a Japanese population. Am J Epidemiol 2011; 174: 1391-5.
56. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006; 38: 652-8.
57. Gudmundsson J, Sulem P, Gudbjartsson DF, Blondal T, Gylfason A, et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet 2009; 41: 1122-6.
58. Gudmundsson J, Sulem P, Gudbjartsson DF, Masson G, Agnarsson BA, et al. A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. Nat Genet 2012; 44: 1326-9.
59. Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 2009; 41: 1058-60.
60. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 1087-93.
61. Haiman CA, Le Marchand L, Yamamato J, Stram DO, Sheng X, et al. A common genetic risk factor for colorectal and prostate cancer. Nat Genet 2007; 39: 954-6.
62. Terada N, Tsuchiya N, Ma Z, Shimizu Y, Kobayashi T, et al. Association of genetic polymorphisms at 8q24 with the risk of prostate cancer in a Japanese population. Prostate 2008; 68: 1689-95.
63. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-8.
64. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006; 66: 3396-400.
65. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009; 41: 619-24.
66. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol 2011; 29: 3659-68.
67. Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate 2011; 71: 489-97.
68. Xue L, Mao X, Ren G, Stankiewicz E, Kudahetti SC, et al. Chinese and Western prostate cancers show alternate pathogenetic pathways in association with ERG status. Am J Cancer Res 2012; 2: 736-44.
69. Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 2009; 218: 505-13.
70. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4: 209-21.
71. Mao X, Yu Y, Boyd LK, Ren G, Lin D, et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res 2010; 70: 5207-12.
72. Orikasa K, Fukushige S, Hoshi S, Orikasa S, Kondo K, et al. Infrequent genetic alterations of the PTEN gene in Japanese patients with sporadic prostate cancer. J Hum Genet 1998; 43: 228-30.
73. Shen Y, Lu Y, Yin X, Zhu G, Zhu J. KRAS and BRAF mutations in prostate carcinomas of Chinese patients. Cancer Genet Cytogenet 2010; 198: 35-9.
74. Watanabe M, Shiraishi T, Yatani R, Nomura AM, Stemmermann GN. International comparison on ras gene mutations in latent prostate carcinoma. Int J Cancer 1994; 58: 174-8.
75. Ren G, Liu X, Mao X, Zhang Y, Stankiewicz E, et al. Identification of frequent BRAF copy number gain and alterations of RAF genes in Chinese prostate cancer. Genes Chromosomes Cancer 2012; 51: 1014-23.
76. Stanford JL, Stephenson RA, Coyle LM, Cerhan J, Correa R, et al. Prostate Cancer Trends 1973-1995, SEER Program. Bethesda, MD, USA: National Cancer Institute, NIH; 1999. p. 99-4543.
77. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009; 101: 1325-9.
78. Li J, Djenaba JA, Soman A, Rim SH, Master VA. Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007. Prostate Cancer 2012; 2012: 691380.
79. Vickers AJ, Cronin AM, Roobol MJ, Hugosson J, Jones JS, et al. The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res 2010; 16: 4374-81.
80. Guan M, Sun SL, Xie RH, Huang ZP, Wen SW, et al. [Age-specific reference ranges for prostate specific antigen in 16 222 Chinese men]. Beijing Da Xue Xue Bao 2011; 43: 586-90.
81. Na R, Jiang H, Kim ST, Wu Y, Tong S, et al. Outcomes and trends of prostate biopsy for prostate cancer in Chinese men from 2003 to 2011. PLoS One 2012; 7: e49914.
82. Wu TT, Huang JK. The clinical usefulness of prostate-specific antigen (PSA) level and age-specific PSA reference ranges for detecting prostate cancer in Chinese. Urol Int 2004; 72: 208-11.
83. Amirrasouli H, Kazerouni F, Sanadizade M, Sanadizade J, Kamalian N, et al. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population. Urol J 2010; 7: 99-104.
84. Wang Y, Sun G, Pan JG, Guo ZJ, Li T. Performance of tPSA and f/tPSA for prostate cancer in Chinese. a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2006; 9: 374-8.
85. Lam JS, Cheung YK, Benson MC, Goluboff ET. Comparison of the predictive accuracy of serum prostate specific antigen levels and prostate specific antigen density in the detection of prostate cancer in Hispanic-American and white men. J Urol 2003; 170: 451-6.
86. Sakai I, Harada K, Hara I, Eto H, Miyake H. Limited usefulness of the free-to-total prostate-specific antigen ratio for the diagnosis and staging of prostate cancer in Japanese men. Int J Clin Oncol 2004; 9: 64-7.
87. Zheng XY, Xie LP, Wang YY, Ding W, Yang K, et al. The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4-10 ng/mL. J Cancer Res Clin Oncol 2008; 134: 1207-10.
88. Cao DL, Ye DW, Zhang HL, Zhu Y, Wang YX, et al. A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer. Prostate 2011; 71: 700-10.
89. Kamidono S, Ohshima S, Hirao Y, Suzuki K, Arai Y, et al. Evidence-based clinical practice Guidelines for Prostate Cancer (Summary-JUA 2006 Edition). Int J Urol 2008; 15: 1-18.
90. Lee SE, Kim DS, Lee WK, Park HZ, Lee CJ, et al. Application of the Epstein criteria for prediction of clinically insignificant prostate cancer in Korean men. BJU Int 2010; 105: 1526-30.
91. Kakehi Y, Kamoto T, Shiraishi T, Ogawa O, Suzukamo Y, et al. Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol 2008; 38: 122-8.
92. Sugimoto M, Shiraishi T, Tsunemori H, Demura T, Saito Y, et al. Pathological findings at radical prostatectomy in Japanese prospective active surveillance cohort. Jpn J Clin Oncol 2010; 40: 973-9.
93. Lee DH, Jung HB, Lee SH, Rha KH, Choi YD, et al. Comparison of pathological outcomes of active surveillance candidates who underwent radical prostatectomy using contemporary protocols at a high-volume Korean center. Jpn J Clin Oncol 2012; 42: 1079-85.
94. Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 2004; 101: 2001-5.
95. Jeldres C, Suardi N, Walz J, Hutterer GC, Ahyai S, et al. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol 2008; 54: 1306-13.
96. Yeom CD, Lee SH, Park KK, Park SU, Chung BH. Are clinically insignificant prostate cancers really insignificant among Korean men? Yonsei Med J 2012; 53: 358-62.
97. Chung JS, Choi HY, Song HR, Byun SS, Seo SI, et al. Nomogram to predict insignificant prostate cancer at radical prostatectomy in Korean men: a multi-center study. Yonsei Med J 2011; 52: 74-80.
98. Lee DH, Koo KC, Lee SH, Rha KH, Choi YD, et al. Tumor lesion diameter on diffusion weighted magnetic resonance imaging could help predict insignificant prostate cancer in patients eligible for active surveillance: preliminary analysis. J Urol 2013; 190: 1213-7.
99. Ogawa K, Nakamura K, Sasaki T, Onishi H, Koizumi M, et al. Radical external beam radiotherapy for clinically localized prostate cancer in Japan: changing trends in the patterns of care process survey. Int J Radiat Oncol Biol Phys 2011; 81: 1310-8.
100. Nakamura K, Mizowaki T, Imada H, Karasawa K, Uno T, et al. External-beam radiotherapy for localized or locally advanced prostate cancer in Japan: a multi-institutional outcome analysis. Jpn J Clin Oncol 2008; 38: 200-4.
101. Yokomizo A, Murai M, Baba S, Ogawa O, Tsukamoto T, et al. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan. BJU Int 2006; 98: 549-53.
102. Sasaki T, Nakamura K, Ogawa K, Onishi H, Otani Y, et al. Postoperative radiotherapy for patients with prostate cancer in Japan; Changing trends in national practice between 1996-98 and 1999-2001: patterns of care study for prostate cancer. Jpn J Clin Oncol 2006; 36: 649-54.
103. Luo HC, Cheng HH, Lin GS, Fu ZC, Li DS. Intensity-modulated radiotherapy combined with endocrine therapy for intermediate and advanced prostate cancer: long-term outcome of Chinese patients. Asian Pac J Cancer Prev 2013; 14: 4711-5.
104. Mottet N, Peneau M, Mazeron JJ, Molinie V, Richaud P. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol 2012; 62: 213-9.
105. Ohashi T, Yorozu A, Saito S, Momma T, Toya K, et al. Outcomes following iodine-125 prostate brachytherapy with or without neoadjuvant androgen deprivation. Radiother Oncol 2013; 109: 241-5.
106. Goldner G, Pötter R, Battermann JJ, Kirisits C, Schmid MP, et al. Comparison between external beam radiotherapy (70 Gy/74 Gy) and permanent interstitial brachytherapy in 890 intermediate risk prostate cancer patients. Radiother Oncol 2012; 103: 223-7.
107. Yamoah K, Stone N, Stock R. Impact of race on biochemical disease recurrence after prostate brachytherapy. Cancer 2011; 117: 5589-600.
108. Ohashi T, Yorozu A, Saito S, Momma T, Nishiyama T, et al. Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer. Radiat Oncol 2014; 9: 13.
109. Park DS, Gong IH, Choi DK, Hwang JH, Shin HS, et al. Outcomes of Gleason Score=8 among high risk prostate cancer treated with 125I low dose rate brachytherapy based multimodal therapy. Yonsei Med J 2013; 54: 1207-13.
110. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364: 1708-17.
111. Lim SK, Kim KH, Shin TY, Rha KH. Current status of robot-assisted laparoscopic radical prostatectomy: how does it compare with other surgical approaches? Int J Urol 2013; 20: 271-84.
112. Ploussard G, de la Taille A, Moulin M, Vordos D, Hoznek A, et al. Comparisons of the perioperative, functional, and oncologic outcomes after robot-assisted versus pure extraperitoneal laparoscopic radical prostatectomy. Eur Urol 2014; 65: 610-9.
113. Ficarra V, Novara G, Rosen RC, Artibani W, Carroll PR, et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 2012; 62: 405-17.
114. Ficarra V, Novara G, Ahlering TE, Costello A, Eastham JA, et al. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. Eur Urol 2012; 62: 418-30.
115. Yip SKh, Sim HG. Robotic radical prostatectomy in East Asia: development, surgical results and challenges. Curr Opin Urol 2010; 20: 80-5.
116. Ham WS, Park SY, Rha KH, Kim WT, Choi YD. Robotic radical prostatectomy for patients with locally advanced prostate cancer is feasible: results of a single-institution study. J Laparoendosc Adv Surg Tech A 2009; 19: 329-32.
117. Eastham JA, Scardino PT, Kattan MW. Predicting an optimal outcome after radical prostatectomy: the trifecta nomogram. J Urol 2008; 179: 2207-10.
118. Krambeck AE, DiMarco DS, Rangel LJ, Bergstralh EJ, Myers RP, et al. Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot-assisted techniques. BJU Int 2009; 103: 448-53.
119. Ploussard G, de la Taille A, Xylinas E, Allory Y, Vordos D, et al. Prospective evaluation of combined oncological and functional outcomes after laparoscopic radical prostatectomy: trifecta rate of achieving continence, potency and cancer control at 2 years. BJU Int 2011; 107: 274-9.
120. Patel VR, Sivaraman A, Coelho RF, Chauhan S, Palmer KJ, et al. Pentafecta: a new concept for reporting outcomes of robot-assisted laparoscopic radical prostatectomy. Eur Urol 2011; 59: 702-7.
121. Chan SW, Lam KM, Kwok SC, Yu C, Au WH, et al. Laparoscopic radical prostatectomy: single centre experience after 5 years. Hong Kong Med J 2008; 14: 192-7.
122. Ko YH, Ban JH, Kang SH, Park HS, Lee JG, et al. Does robot-assisted laparoscopic radical prostatectomy enable to obtain adequate oncological and functional outcomes during the learning curve? From the Korean experience. Asian J Androl 2009; 11: 167-75.
123. Lo KL, Ng CF, Lam CN, Hou SS, To KF, et al. Short-term outcome of patients with robot-assisted versus open radical prostatectomy: for localised carcinoma of prostate. Hong Kong Med J 2010; 16: 31-5.
124. Park JW, Won Lee H, Kim W, Jeong BC, Jeon SS, et al. Comparative assessment of a single surgeon's series of laparoscopic radical prostatectomy: conventional versus robot-assisted. J Endourol 2011; 25: 597-602.
125. Imamoto T, Goto Y, Utsumi T, Fuse M, Kawamura K, et al. Complications, urinary continence, and oncologic outcomes of laparoscopic radical prostatectomy: single-surgeon experience for the first 100 cases. Prostate Cancer 2011; 2011: 606505.
126. Yip KH, Yee CH, Ng CF, Lam NY, Ho KL, et al. Robot-assisted radical prostatectomy in Hong Kong: a review of 235 cases. J Endourol 2012; 26: 258-63.
127. Ou YC, Yang CK, Wang J, Hung SW, Cheng CL, et al. The trifecta outcome in 300 consecutive cases of robotic-assisted laparoscopic radical prostatectomy according to D'Amico risk criteria. Eur J Surg Oncol 2013; 39: 107-13.
128. Yao XD, Liu XJ, Zhang SL, Dai B, Zhang HL, et al. Perioperative complications of radical retropubic prostatectomy in patients with locally advanced prostate cancer: a comparison with clinically localized prostate cancer. Asian J Androl 2013; 15: 241-5.
129. Choo MS, Choi WS, Cho SY, Ku JH, Kim HH, et al. Impact of prostate volume on oncological and functional outcomes after radical prostatectomy: robot-assisted laparoscopic versus open retropubic. Korean J Urol 2013; 54: 15-21.
130. Namiki S, Kwan L, Kagawa-Singer M, Tochigi T, Ioritani N, et al. Sexual function following radical prostatectomy: a prospective longitudinal study of cultural differences between Japanese and American men. Prostate Cancer Prostatic Dis 2008; 11: 298-302.
131. Namiki S, Arai Y. Sexual quality of life for localized prostate cancer: a cross-cultural study between Japanese and American men. Reprod Med Biol 2011; 10: 59-68.
132. Hong SK, Doo SH, Kim DS, Lee WK, Park HZ, et al. The 5-year functional outcomes after radical prostatectomy: a real-life experience in Korea. Asian J Androl 2010; 12: 835-40.
133. Namiki S, Carlile RG, Namiki TS, Fukagai T, Takegami M, et al. Racial differences in sexuality profiles among American, Japanese, and Japanese American men with localized prostate cancer. J Sex Med 2011; 8: 2625-31.
134. Namiki S, Ishidoya S, Ito A, Kawamura S, Tochigi T, et al. Quality of life after radical prostatectomy in Japanese men: a 5-Year follow up study. Int J Urol 2009; 16: 75-81.
135. Namiki S, Arai Y. Health-related quality of life in men with localized prostate cancer. Int J Urol 2010; 17: 125-38.
136. Fukagai T, Namiki TS, Carlile RG, Yoshida H, Namiki M. Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int 2006; 97: 1190-3.
137. Fukagai T, Namiki T, Carlile RG, Namiki M. Racial differences in clinical outcome after prostate cancer treatment. Methods Mol Biol 2009; 472: 455-66.
138. Fujimoto N, Kubo T, Inatomi H, Bui HT, Shiota M, et al. Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation. Prostate Cancer Prostatic Dis 2013; 16: 336-40.
139. Wang W, Yuasa T, Tsuchiya N, Maita S, Kumazawa T, et al. Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocr Relat Cancer 2008; 15: 943-52.
140. Yuasa T, Maita S, Tsuchiya N, Ma Z, Narita S, et al. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology 2010; 75: 1131-7.
141. Bruder JM, Ma JZ, Basler JW, Welch MD. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology 2006; 67: 152-5.
142. Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 2007; 69: 500-4.
143. Namiki M, Ueno S, Kitagawa Y, Fukagai T, Akaza H. Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspective. Asian J Androl 2012; 14: 451-7.
144. Liu L, Miura K, Fujiyoshi A, Kadota A, Miyagawa N, et al. Impact of metabolic syndrome on the risk of cardiovascular disease mortality in the United States and in Japan. Am J Cardiol 2014; 113: 84-9.
145. Senoo K, Suzuki S, Sagara K, Otsuka T, Matsuno S, et al. Coronary artery diseases in Japanese patients with nonvalvular atrial fibrillation. J Cardiol 2014; 63: 123-7.
146. Murakoshi N, Aonuma K. Epidemiology of arrhythmias and sudden cardiac death in Asia. Circ J 2013; 77: 2419-31.
147. Qu YY, Dai B, Kong YY, Ye DW, Yao XD, et al. Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Asian J Androl 2013; 15: 110-5.
148. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
149. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.
150. Lee JL, Kim JE, Ahn JH, Lee DH, Lee J, et al. Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea. Cancer Res Treat 2010; 42: 12-7.
151. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-5.
152. Shimazui T, Kawai K, Miyanaga N, Kojima T, Sekido N, et al. Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone. Jpn J Clin Oncol 2007; 37: 603-8.
153. Naito S, Tsukamoto T, Koga H, Harabayashi T, Sumiyoshi Y, et al. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. Jpn J Clin Oncol 2008; 38: 365-72.
154. Miyake H, Sakai I, Harada K, Muramaki M, Fujisawa M. Significance of docetaxel-based chemotherapy as treatment for metastatic castration-resistant prostate cancer in Japanese men over 75 years old. Int Urol Nephrol 2012; 44: 1697-703.
155. Li YF, Zhang SF, Zhang TT, Li L, Gan W, et al. Intermittent tri-weekly docetaxel plus bicalutamide in patients with castration-resistant prostate cancer: a single-arm prospective study using a historical control for comparison. Asian J Androl 2013; 15: 773-9.
156. Wailoo A, Sutton A, Morgan A. The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis. Br J Cancer 2009; 100: 436-41.
157. Miura N, Numata K, Kusuhara Y, Shirato A, Hashine K, et al. Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience. Jpn J Clin Oncol 2010; 40: 1092-8.
158. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002; 20: 3683-90.
159. Bruno R, Vivier N, Veyrat-Follet C, Montay G, Rhodes GR. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs 2001; 19: 163-9.
160. Konishi N, Hiasa Y, Tsuzuki T, Tao M, Enomoto T, et al. Comparison of ras activation in prostate carcinoma in Japanese and American men. Prostate 1997; 30: 53-7.
161. Moyret-Lalle C, Marçais C, Jacquemier J, Moles JP, Daver A, et al. Ras, p53 and HPV status in benign and malignant prostate tumors. Int J Cancer 1995; 64: 124-9.
162. Liu T, Willmore-Payne C, Layfield LJ, Holden JA. Lack of BRAF activating mutations in prostate adenocarcinoma: a study of 93 cases. Appl Immunohistochem Mol Morphol 2009; 17: 121-5.